|View printer-friendly version|
|June 17, 2004 5:08 p.m.|
|Teva And Aventis Announce That Copaxone ® Pre-Filled Syringe Is Now Available Also In Europe|
Combined with COPAXONE® sustained effect, the pre-filled syringe form significantly improves quality of life for patients with Multiple Sclerosis
Jerusalem, Israel, June 17, 2004 - Teva Pharmaceutical Industries Ltd. and Aventis Pharma today announced that the Multiple Sclerosis (MS) therapy COPAXONE® (glatiramer acetate injection) is now available also in Europe in a pre-filled, ready-to-use syringe (PFS). For physicians, nurses and pharmacists, compliance and adherence to treatment are among the most important factors in any therapy. With COPAXONE® PFS, injection will be faster and more convenient. No mixing or preparation is required, and fewer supplies are needed, ensuring increased accuracy, better compliance, and reduced risk of contamination.